کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4138624 | 1272160 | 2008 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
KRAS mutational testing in the selection of patients for EGFR-targeted therapies
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
آسیبشناسی و فناوری پزشکی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and the anti-EGFR monoclonal antibodies have proven activity in lung and colorectal adenocarcinomas, respectively, but only a small fraction of patients exhibit significant responses. The observation that only a minority of patients respond to EGFR-targeted therapies, in combination with their toxicity and high costs, has driven the search for molecular markers predictive of response. The main focus of the present review is the recent discovery that mutations in the KRAS oncogene constitute a negative predictive marker in this clinical setting, namely that their presence can be used to predict which patients are unlikely to benefit from treatment with EGFR-directed therapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Seminars in Diagnostic Pathology - Volume 25, Issue 4, November 2008, Pages 288-294
Journal: Seminars in Diagnostic Pathology - Volume 25, Issue 4, November 2008, Pages 288-294
نویسندگان
Joaquin Garcia, Gregory J. Riely, Khedoudja Nafa, Marc MD,